Cinven acquires international niche pharmaceuticals business

European private equipment company Cinven has acquired the Amdipharm Group, an international niche pharmaceuticals business, for a total consideration of £367m.

Amdipharm will operate initially as a standalone business, but over time Cinven will look to merge the operation with its existing portfolio company Mercury Pharma, which it acquired in September 2012.

Mercury and Amdipharm each market mature, niche pharmaceuticals — both branded and unbranded. The businesses are said to be complementary as Mercury’s customer base is largely UK focused, whereas Amdipharm has a significantly greater international business, with its products sold in more than 80 countries worldwide.